Positron emission tomography (PET) and magnetic resonance imaging (MRI) are major tools of the clinical diagnostician and the basic research scientist. They offer non-destructive three-dimensional (3D) views into deep tissues. PET, through the use of radiolabeled molecular probes can sensitively assay a range of biological processes (e.g. metabolic activity, receptor density, signal transduction) with high signal-to-noise ratio (SNR) and millimeter spatial resolution. MRI is exquisitely sensitive to soft tissue differences and abnormalities with resolution as fine as 105m in small samples. Although SNR is intrinsically low in the magnetic resonance (MR) experiment, new MRI contrast agents offer the potential of monitoring specific biological processes at high resolution, albeit at a significantly lower sensitivity than PET. Given the complementary strengths of these imaging modalities it was logical to consider integrating the two. The notion of combining these two modalities in a single instrument to allow simultaneous PET &MRI data collection was considered a curiosity at beginning of our Bioengineering Research Partnership (BRP) in 2004. Now, just four years later, there are two completed small animal PET/MRI systems (one developed by this BRP, the other in collaboration with this BRP) that have been used for a significant number of proof-of-concept in vivo studies;and the first PET/MRI system for human brain imaging has recently been developed by industry. Although PET/MRI has now become a "hot topic" in imaging, performance of the systems leaves much to desired and the quantitative potential of this technology for biological research has not yet been realized. The goal of this renewal is to develop a very high performance integrated 5PET/5MRI system, in which the performance of the 5PET component matches or exceeds that of commercially available standalone 5PET systems without significantly affecting the performance of the 5MR system. PET and MR data acquisition will be synchronized with each other and with physiologic monitoring triggers from subjects, thus providing the highest quality simultaneous in vivo 5PET/5MRI imaging. Real-time image reconstruction and alignment tools will provide melded PET/MR images while the experiment is in progress with data being archived and filed in an online database for intuitive and facile future access. This informatics infrastructure will provide straightforward exchange of information between collaborators and with the scientific community. In conjunction with hardware developments, we will develop techniques for highly quantitative PET/MRI studies, continue to design advanced novel dual-modality imaging agents, and we will apply our technologies, tools, and methods to assess important biological questions in animal models of human disease. The work in this BRP will continue to lay the scientific foundation for the broader application of PET/MRI technology in basic research and in the clinic.

Public Health Relevance

This proposal seeks to develop an innovative and high performance in vivo imaging system that simultaneously combines the high sensitivity of positron emission tomography (PET) with the high spatial resolution of magnetic resonance imaging (MRI). This will allow temporal and spatial correlation of PET and MR signals for a wide range of biomedical applications including whole-body dynamic tracking of cells, high sensitivity detection of reporter gene expression and quantitative interrogation of molecular targets in living subjects. While the focus of our work is in the preclinical realm, the development of the first human PET/MR systems by industry emphasizes the importance of developing the translational capabilities of PET/MRI and having a preclinical platform on which to test and validate new approaches for evaluating novel therapeutics, biomarkers and diagnostics that are ultimately destined for clinical use.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Research Project (R01)
Project #
5R01EB000993-09
Application #
8299025
Study Section
Special Emphasis Panel (ZRG1-SBIB-V (50))
Program Officer
Sastre, Antonio
Project Start
2003-04-01
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
9
Fiscal Year
2012
Total Cost
$1,052,834
Indirect Cost
$207,766
Name
California Institute of Technology
Department
None
Type
Schools of Arts and Sciences
DUNS #
009584210
City
Pasadena
State
CA
Country
United States
Zip Code
91125
Ouyang, Yu; Tinianow, Jeff N; Cherry, Simon R et al. (2014) Evaluation of 2-[ยน?F]fluoroacetate kinetics in rodent models of cerebral hypoxia-ischemia. J Cereb Blood Flow Metab 34:836-44
Tu, Chuqiao; Ng, Thomas S C; Jacobs, Russell E et al. (2014) Multimodality PET/MRI agents targeted to activated macrophages. J Biol Inorg Chem 19:247-58
Ren, Silin; Yang, Yongfeng; Cherry, Simon R (2014) Effects of reflector and crystal surface on the performance of a depth-encoding PET detector with dual-ended readout. Med Phys 41:072503
Peng, Bo J; Wu, Yibao; Cherry, Simon R et al. (2014) New shielding configurations for a simultaneous PET/MRI scanner at 7T. J Magn Reson 239:50-6
Malkova, Natalia V; Gallagher, Joseph J; Yu, Collin Z et al. (2014) Manganese-enhanced magnetic resonance imaging reveals increased DOI-induced brain activity in a mouse model of schizophrenia. Proc Natl Acad Sci U S A 111:E2492-500
Ng, Thomas S C; Wert, David; Sohi, Hargun et al. (2013) Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101. Clin Cancer Res 19:2518-27
Louie, Angelique (2013) MRI biosensors: a short primer. J Magn Reson Imaging 38:530-9
Andreozzi, Erica; Wang, Peter; Valenzuela, Anthony et al. (2013) Size-stable solid lipid nanoparticles loaded with Gd-DOTA for magnetic resonance imaging. Bioconjug Chem 24:1455-67
Tu, Chuqiao; Louie, Angelique Y (2012) Nanoformulations for molecular MRI. Wiley Interdiscip Rev Nanomed Nanobiotechnol 4:448-57
MacKenzie-Graham, Allan J; Rinek, Gilda A; Avedisian, Andrea et al. (2012) Estrogen treatment prevents gray matter atrophy in experimental autoimmune encephalomyelitis. J Neurosci Res 90:1310-23

Showing the most recent 10 out of 29 publications